Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Protagen closes new round of financing to strengthen technology position for novel diagnostics


Dortmund, Germany and New Jersey, USA, August 1, 2008: Protagen AG, a leading provider of GMP compliant protein analytical services, protein bio­informatics, and protein biochips announces the closing of a new round of financing. The capital will be used to strengthen and expand the company’s UNIarray® technology position and the development of novel diagnostics. The capital raised in this round has come from the existing institutional investors, MIG AG, Munich, S-Venture Capital Dortmund GmbH, and Kreditanstalt für Wiederaufbau (KfW).

Background: UNIarray® is a unique technology platform for the development of novel diagnostics based on indication specific autoantibody patterns in patient sera. These indication specific autoantibody patterns were already proven to be present in several autoimmune diseases, but also in cancer, neurodegenerative disorders, and even in apparently healthy individuals. Therefore, the systematic and indication-specific determination of autoanti­body patterns will serve as a unique basis to address hitherto unmet dia­gnostic needs. In addition, UNIarray® serves as a platform for the develop­ment of product specific companion diagnostics and patient stratification for clinical studies. In-house research at Protagen is presently focused on novel diagnostics for prostate cancer, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, Morbus Parkinson, and Alzheimer’s.

At the same time Dr. Christoph Hüls (CEO) will leave Protagen for private reasons and will move to a new position in a large pharmaceutical company. The Chairman of the Board of Protagen AG, Prof. Axel Kleemann, regrets the departure of Christoph Hüls and the end of a long and trustful cooperation. Dr. Stefan Müllner (CSO) will take over the position as new CEO.

-ends-

About Protagen AG
Protagen AG (www.protagen.de) is a leading provider of products, services and software solutions for protein research with sites in Dortmund, Germany, and Chester, New Jersey, USA. Technology innovations of Protagen are UNIclone®, a patented platform for development and use of protein expression libraries, and UNIchip®, a versatile and highly efficient family of products for the development of antibodies, as well as UNIarray®, a unique technology base for the development of new diagnostics.


Contact

Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: info@protagen.de


Media Enquiries

Lorna Cuddon, Kathryn Robertson, Holly Griffiths
College Hill

Tel: +44 (0) 20 7457 2020
E-Mail: protagen@collegehill.com


Publisher Contact Information:

Protagen AG
+49 (0) 231 9742 6300
info@protagen.de

Company profile of Protagen AG
Past press releases of Protagen AG.

Data


26,008
Tech investments
From our Online Data Service
16,823
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Aug 19€7.0MAgriculture related
Aug 19€9.0MInternet commerce
Aug 19€10.0ME-Commerce
Aug 19€63.0MBusiness applications
Aug 16€16.0ME-Commerce
Aug 16€6.0MBusiness applications
Aug 15€20.0MGames

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.